April 17, 2015
Baxter Limited, the Japan unit of US-based Baxter International, filed on April 16 a new drug application (NDA) for its extended half-life recombinant factor VIII（rFVIII）treatment BAX 855 in Japan, it said on the same day. The drug was developed based...read more